WO1991018869A1 - Phenyl 4-guanidinobenzoate derivative, process for producing the same, and protease inhibitor containing the same - Google Patents
Phenyl 4-guanidinobenzoate derivative, process for producing the same, and protease inhibitor containing the same Download PDFInfo
- Publication number
- WO1991018869A1 WO1991018869A1 PCT/JP1991/000773 JP9100773W WO9118869A1 WO 1991018869 A1 WO1991018869 A1 WO 1991018869A1 JP 9100773 W JP9100773 W JP 9100773W WO 9118869 A1 WO9118869 A1 WO 9118869A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hydrogen atom
- group
- alkyl group
- general formula
- atom
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/63—Esters of sulfonic acids
- C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
- C07C309/67—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/18—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Definitions
- the present invention relates to a novel 4 guanidinobenzoic acid phenyl ester derivative, and more particularly, to a 4-guanidinobenzoic acid phenyl ester derivative having proteolytic enzyme inhibitory activity or a pharmacologically acceptable acid addition salt thereof.
- the present invention relates to a method for producing the same and a protein degrading enzyme inhibitor containing the same as an active ingredient.
- Sores are clinically classified into acute sores and chronic sores.
- acute ulcers the spleen normalizes both clinically and biologically when the causative factors or factors are eliminated.
- chronic sores it is said that histological or functional changes remain even if the cause or factor of the onset of the disease disappears.
- alcohol is the most common, followed by unclear cause (idiopathic) and gallstone.
- the present invention aims to develop a substance having a proteolytic enzyme inhibitory effect far superior to that of conventional antiproteolytic enzyme agents, a process for producing the same, and a proteolytic enzyme inhibitor useful as various pharmaceuticals containing them as active ingredients. To aim.
- the inventors of the present invention have conducted extensive studies to solve the above-mentioned problems, and as a result, the 4-guanidinobenzoic acid phenyl ester derivative represented by the novel general formula (I) was found to be bound with tripsin, thrombin, It has a strong anti-allergic activity against various serine proteases with a wide spectrum such as plasmids, calcium lines, factor Xa and elastase.
- the present invention has been completed and the present invention has been completed.
- R 1 is a hydrogen atom or a halogen atom
- R 2 is a trifluoromethoxy group, 0C0R 3 , C NOR 4
- R 4 is hydrogen atom, d-4 alkyl groups
- R 5 is a hydrogen atom or a C Bok 4 alkyl group
- R 41 is a hydrogen atom or d — 4 Represents an alkyl group.
- the present invention provides a protease inhibitor.
- the above-mentioned pharmacologically acceptable acid addition salts are specifically inorganic acids such as hydrochloride, hydrobromide, hydroiodide, sulfate, perchlorate, phosphate, and nitrate.
- Organic salts such as addition salts, acetates, oxalates, maleates, fumarates, succinates, metal sulphonates, ethane sulphonates and toluene sulphonates Mention may be made of acid addition salts.
- the compound of the present invention represented by the general formula (I) can be prepared, for example, by the general formula ( ⁇ ) ' 4 — guanidinobenzoic acid or a reactive derivative thereof and a compound of the general formula (m)
- a compound represented by (IV) [for example, easily obtained by heating the compound ( ⁇ ) with ⁇ onyl chloride]
- H 2 N— C-NH—> — COHal (IV) (Wherein Ha l represents a halogen atom such as chlorine, bromine, iodine, etc.) is reacted with a compound of general formula (1 ⁇ ) in the presence of an acid binder such as pyridin, triethylamine.
- an acid binder such as pyridin, triethylamine.
- the solvent used in this method is an aqueous medium or an organic solvent, for example, an ether solvent such as ether or tetrahydrofuran, an aromatic solvent such as benzene or toluene, or a heterocyclic system such as pyridin.
- Solvents non-protonic polar solvents such as N> N — dimethylformamide, N, N — dimethylacetamide, dimethylsulfoxide and the like can be mentioned.
- pyridin is the most suitable, and when a solvent other than pyridin is used, triethylamine, tributylamine, dimethylamine, pyridin, etc. can be used as the acid binder.
- Inorganic bases such as organic bases, calcium carbonate, sodium carbonate, and sodium hydroxide can be used.
- 4 guanidinobenzoic acid represented by the general formula ( ⁇ ) and a compound represented by the general formula (H), for example, DCC (1, 3 — dicyclohexylcarboimide ), EDC [1-ethyl 3- (3-dimethylaminopropyl) carbamide hydrochloride) or the like in the presence of a dehydrating agent or the like, in the absence of a solvent or an organic solvent, it is also possible to directly condense.
- DCC 1, 3 — dicyclohexylcarboimide
- EDC 1-ethyl 3- (3-dimethylaminopropyl) carbamide hydrochloride
- the compound of the present invention of general formula (I) obtained by such a method can be appropriately derivatized into a pharmaceutically acceptable acid addition salt by a conventional method.
- Hydrochloride hydrobromide, hydroiodide, sulfate, perchlorate, phosphate, nitrate and other inorganic acid salts, acetate, oxalate, maleic acid It can be easily derivatized to salts of organic acids such as salts, fumarates, succinates, methsulphonates, ethansulphonates, trisulphonates. is there.
- (40) 3 Closine 1 — — Styrene sulfonyloxy) phenyl 4-guanidino benzoate
- the compound of the general formula (I) and its pharmaceutically acceptable acid addition salts are tributine, trophine It has an extremely strong inhibitory effect on enzymes such as vinegar, plasmin, factor Xa and elastase.
- the compound of the present invention When the compound of the present invention is described above as a therapeutic agent for these diseases and is administered to this patient, the type of disease, the degree of symptoms, the age of the patient, the health of the patient, and the like. Health status, body weight, type of concurrent treatment, if any, frequency of treatment, which depends on the nature of the desired effect, etc., and is not particularly limited, but usually about 5 to 1000 ig per adult per day, preferably about 10 ⁇ 500 mg is given orally or parenterally once daily or more.
- dosage forms include powders, fine granules, granules, tablets, capsules, suppositories, injections and the like. Upon formulation, it is manufactured by a conventional method using a usual pharmaceutical carrier.
- the excipients include, for example, lactose, corn starch, sucrose, glucose, sorbit, crystalline cellulose, silicon dioxide, etc.
- the binders include, for example, polyvinyl alcohol, polyvinyl alcohol. -Nore, etinorece noreose, methinorecenore mouth, arabia rubber-tragant, gelatin, shella, hydroxip mouth pircerulose, hydroxylprobi starch, po
- disintegrating agents such as polyvinylpyrrolidone include starch, agar, gelatin powder, crystalline cellulose, calcium carbonate, sodium hydrogen carbonate, calcium quatate, fiber.
- lubricants such as calcium darukonate and dextrin pectin are magnesium stearate, talc, polyethylene glycol, silica, hardened vegetable oil, etc.
- coloring agents those permitted to be added to pharmaceuticals are used, and as flavoring agents, cocoa powder, coconut oil, aromatic acids, cinnamon powder, etc. are used. it can.
- these tablets and granules may be sugar-coated, gelatin-coated, or coated as needed according to need.
- R 1 represents H
- R 2 represents 4 trifluoromethoxy or 3-trifluoromethoxy.
- R represents 3 —C £ or HR 2 represents 5 —cyclohexylcarbonyloxy or 3 _ (1 —methoxyiminoethyl).
- Table 2 Physical properties
- Compound 39 10 g, fibrin calcium dalconate (disintegrant) 400 mg, magnesium stearate (lubricant) 200 mg, and crystalline cellulose 9.4 g were mixed by a conventional method and compressed into tablets. Thus, 100 tablets each containing 100 mg of the active ingredient of lOOni were obtained.
- the contents of the sample are diluted with an appropriate volume of diluting solution, for example, Tris-HCl buffer of pH 8.6 to 2.5 m and used as an injection.
- Typical compounds of the compound (I) of the present invention (compounds 39, 3, 2, 2, 26, 31 and 10), trypticine, thrombin, plasmin, The factor Xa and elastase inhibitory activity was measured by a slight modification based on the method described in JP-A-2-101017.
- the enzymatic reaction was carried out in 0.2 M Tris-HCl buffer (containing 0.02 M CaC, 0.005% Triton X — 100), and trypsin, thrombin, plasmin, and ph
- the pH was measured at pH 8.0 for Eq. Xa and at pH 7.2 for elastase.
- trypsin a mixture of the sample solution and enzyme solution was incubated at .25 K for 60 minutes, and for other enzymes, at 20 ° C for 20 minutes.
- the compound described in JP-A-51-138642 was used as Comparative Example 1, and the compound described in JP-A-63-165357 was used as Comparative Example 2.
- the results are shown in Table 3.
- the compound of the present invention has a strong inhibitory effect on excellent enzymes such as trypsin, thrombin, plasmin, and factor) (a and elastase. It became clear that they had it.
- LD 5 of the compound of the present invention was obtained.
- the values were 50 to 200 mg Zkg in all cases.
- the toxicity of the compound of the present invention is sufficiently low, and it was confirmed that the compound of the present invention can be used safely as a drug.
- a polyvinyl vinyl chloride formulation (20% by weight of the compound of the present invention, 80% by weight of polyvinylpyrrolidone of the present invention) was prepared using Compound 39, and was orally administered 15 minutes before administration of cellulene as an aqueous solution (UOmg / ffiC). It was
- the compounds of the general formula (I) of the present invention and their pharmaceutically acceptable acid addition salts are, for example, trypsin, thrombin, plasmin, force reclaim, factor Xa and elastase. It has a strong inhibitory activity against various serine rotases such as It is useful as an anti-trypsin agent effective for the treatment of inflammation, an anti-plasmin agent effective for the treatment of hemorrhagic diseases, and an anti-thrombin agent effective for the treatment of blood clots. It is also useful as a new elastase inhibitor.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2148674A JPH0446148A (ja) | 1990-06-08 | 1990-06-08 | 4―グアニジノ安息香酸フェニルエステル誘導体およびそれらを含有する蛋白分解酵素阻害剤 |
JP2/148674 | 1990-06-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1991018869A1 true WO1991018869A1 (en) | 1991-12-12 |
Family
ID=15458082
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1991/000773 WO1991018869A1 (en) | 1990-06-08 | 1991-06-07 | Phenyl 4-guanidinobenzoate derivative, process for producing the same, and protease inhibitor containing the same |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0486702A1 (ja) |
JP (1) | JPH0446148A (ja) |
AU (1) | AU7962091A (ja) |
CA (1) | CA2064462A1 (ja) |
WO (1) | WO1991018869A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013039187A1 (ja) | 2011-09-15 | 2013-03-21 | アステラス製薬株式会社 | グアニジノ安息香酸化合物 |
WO2014142219A1 (ja) | 2013-03-13 | 2014-09-18 | アステラス製薬株式会社 | グアニジノ安息香酸エステル化合物 |
US9969705B2 (en) | 2014-02-13 | 2018-05-15 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compound |
US10023544B2 (en) | 2014-02-13 | 2018-07-17 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6066673A (en) * | 1998-03-12 | 2000-05-23 | The Procter & Gamble Company | Enzyme inhibitors |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS53147044A (en) * | 1977-05-25 | 1978-12-21 | Ono Pharmaceut Co Ltd | Guanidinobenzoic acid derivative and its preparation |
JPS55100356A (en) * | 1979-01-29 | 1980-07-31 | Kowa Co | Benzenediol derivative |
JPS63165357A (ja) * | 1985-11-12 | 1988-07-08 | Ono Pharmaceut Co Ltd | p―グアニジノ安息香酸フェニルエステル誘導体 |
-
1990
- 1990-06-08 JP JP2148674A patent/JPH0446148A/ja active Pending
-
1991
- 1991-06-07 WO PCT/JP1991/000773 patent/WO1991018869A1/ja not_active Application Discontinuation
- 1991-06-07 CA CA002064462A patent/CA2064462A1/en not_active Abandoned
- 1991-06-07 EP EP91910649A patent/EP0486702A1/en not_active Withdrawn
- 1991-06-07 AU AU79620/91A patent/AU7962091A/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS53147044A (en) * | 1977-05-25 | 1978-12-21 | Ono Pharmaceut Co Ltd | Guanidinobenzoic acid derivative and its preparation |
JPS55100356A (en) * | 1979-01-29 | 1980-07-31 | Kowa Co | Benzenediol derivative |
JPS63165357A (ja) * | 1985-11-12 | 1988-07-08 | Ono Pharmaceut Co Ltd | p―グアニジノ安息香酸フェニルエステル誘導体 |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013039187A1 (ja) | 2011-09-15 | 2013-03-21 | アステラス製薬株式会社 | グアニジノ安息香酸化合物 |
KR20140061515A (ko) | 2011-09-15 | 2014-05-21 | 아스텔라스세이야쿠 가부시키가이샤 | 구아니디노벤조산 화합물 |
US9199927B2 (en) | 2011-09-15 | 2015-12-01 | Astellas Pharma Inc. | Guanidinobenzoic acid compound |
WO2014142219A1 (ja) | 2013-03-13 | 2014-09-18 | アステラス製薬株式会社 | グアニジノ安息香酸エステル化合物 |
KR20150130392A (ko) | 2013-03-13 | 2015-11-23 | 아스텔라스세이야쿠 가부시키가이샤 | 구아니디노벤조산 에스테르 화합물 |
US9969709B2 (en) | 2013-03-13 | 2018-05-15 | Takeda Pharmaceutical Company Limited | Guanidinobenzoic acid ester compound |
US9969705B2 (en) | 2014-02-13 | 2018-05-15 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compound |
US10023544B2 (en) | 2014-02-13 | 2018-07-17 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
Also Published As
Publication number | Publication date |
---|---|
CA2064462A1 (en) | 1991-12-09 |
JPH0446148A (ja) | 1992-02-17 |
AU7962091A (en) | 1991-12-31 |
EP0486702A1 (en) | 1992-05-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU776053B2 (en) | Diazepan derivatives or salts thereof | |
JP2001507676A (ja) | 抗血栓性有機硝酸塩 | |
WO1991015487A1 (fr) | Nouveau derive de 4-1-benzoxazine-4h-3,1 | |
CA2160423A1 (en) | Salts of nefazodone having improved dissolution rates | |
CN113999234A (zh) | 一种免疫调节剂 | |
JP5325289B2 (ja) | P4サブユニットとしてサイクリックアミドキシム又はサイクリックアミドラゾンを有するfxa阻害剤、この製造方法、及びこの薬学的組成物並びに誘導体 | |
JP2001518506A (ja) | キノリン−含有α−ケトアミドシステインおよびセリンプロテアーゼインヒビター | |
ZA200300998B (en) | Compounds inhibiting factor Xa activity. | |
JP2001525394A (ja) | 新規な化合物 | |
JP2000302765A (ja) | 新規なジアゼパン誘導体又はその塩 | |
WO1991018869A1 (en) | Phenyl 4-guanidinobenzoate derivative, process for producing the same, and protease inhibitor containing the same | |
JPS63264454A (ja) | 新規なプロリナール誘導体 | |
ZA200409228B (en) | New salts. | |
WO2021180023A1 (zh) | 一种弹性蛋白酶抑制剂前药及其用途 | |
JPH01230578A (ja) | プロリルエンドペプチダーゼ阻害剤 | |
JPH0753500A (ja) | グアニジノ安息香酸誘導体及びこれらを有効成分とする蛋白分解酵素阻害剤 | |
JPH0848664A (ja) | 新規なグアニジノ安息香酸エステル誘導体 | |
JP2003529528A (ja) | プロテアーゼインヒビターとしてのアミノ酸アミジノヒドラゾン、アルコキシグアニジン、およびアミノグアニジン | |
US4490388A (en) | Amidine compound and anticomplement agent comprising same | |
JPH05194366A (ja) | グリシン誘導体・モノナトリウム塩・4水和物、その製造方法、それを含有する薬剤および該誘導体の中間体の製造方法 | |
KR960008242B1 (ko) | 벤조옥사디논유도체 | |
CN115160204B (zh) | 一种成纤维细胞活化蛋白抑制剂及其制备方法和应用 | |
US6133297A (en) | Thrombin inhibitors | |
AU740170B2 (en) | Thrombin inhibitors | |
CN107652210B (zh) | 一种胍类化合物或其药学上可接受的盐、其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2064462 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1991910649 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1991910649 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1991910649 Country of ref document: EP |